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Patients with chronic obstructive pulmonary disease (COPD) exhale more hydrogen peroxide (H2O2) and lipid
peroxidation products than healthy subjects. This may reflect oxidative stress in the airways that plays important
role in the development and progression of COPD. N-acetylcysteine (NAC), a mucolytic drug, possesses
antioxidant properties as it is a precursor of reduced glutathione that together with glutathione peroxidase may
decompose H2O2 and lipid peroxides.
We aimed to determine the effect of NAC, 600mg effervescent tablets (Fluimucil), once a day for 12 months, and
placebo on the concentration of H2O2 and thiobarbituric acid reactive substances (TBARs) in expired breath
condensate and serum levels of two lipid peroxidation products (TBARs, lipid peroxides) in patients with COPD.
The study was performed as a double-blind, double-dummy comparison between active drug and placebo in two
parallel groups. Forty-four outpatients with stable COPD (22 in the NAC group and 22 in the placebo group)
completed the study. Specimens of expired breath condensate and serum were collected at the randomization visit
and then every 3 months over 1 year. The concentration of TBARs and H2O2 in expired breath condensate was
measured spectrofluorimetrically by the thiobarbituric acid and homovanillic acid methods, respectively. Serum
levels of lipid peroxides were determined spectrophotometrically after extraction with butanol and pyridine.
Initially, H2O2 exhalation did not differ between the placebo and NAC groups up to 6 months of treatment. After
this the significant differences were observed. After 9 and 12 months of treatment NAC group exhaled 2?3-fold
(0?17+ 0?33 mM vs. 0?41+0?26 mM, P50?04) [median=0?01 mM, quartile range (qr)=0?22 vs. median=0?15 mM,
qr=0?43] and 2?6-fold (0?15+0?23mM vs. 0?40+ 0?25 mM, P50?05) median=0?00mM, qr=0?23 vs. med-
ian=0?36 mM, qr=0?51] less H2O2 than placebo receivers, respectively. No significant effect of NAC administration
on TBARs exhalation and serum levels of TBARs and lipid peroxides were noted over the whole treatment period.
Also no significant associations between exhaled H2O2 and concentrations of lipid peroxidation products were
noted in both treatment groups at any time-point.
These results indicate that long-term oral administration of NAC attenuates H2O2 formation in the airways of
COPD subjects and prove anti-oxidant action of drug. However, further studies are necessary to estimate the
clinical significance of this finding.
Key words: chronic obstructive pulmonary disease; N-acetylcysteine; hydrogen peroxide; lipid peroxidation;
thiobarbituric acid reactive substances; expired breath condensate.
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Oxidative stress that results from imbalance between
oxidants and anti-oxidant capacities plays an importantReceived 24 July 2000 and accepted in revised form 23 February
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0954-6111/01/060448+09 $35?00/0role in the pathogenesis of chronic obstructive pulmonary
disease (COPD) (1). Cigarette smoking, the major factor
responsible for the development of COPD, enhances the
generation of oxidants in the airways by attraction of
activated phagocytes into lung tissue (2,3). Moreover,
cigarette smoke itself is a rich source of oxidants and
free-radicals (4,5) and contains iron that accumulates in
lungs (6,7) which may lead to increased formation of free-
radicals and peroxidative damage to pulmonary parench-
yma. Elevated exhalation of hydrogen peroxide (H2O2) and
volatile lipid peroxidation products (ethane, thiobarbituric# 2001 HARCOURT PUBLISHERS LTD
LONG-TERM USE OF N-ACETYLCYSTEINE IN COPD 449acid reactive substances) by COPD patients and asympto-
matic cigarette smokers (3,8–12) seems to be a consequence
of these processes. However, COPD subjects that were
current smokers did not exhale more H2O2 and thiobarbi-
turic acid reactive substances (TBARs) than COPD
patients that had never smoked (9). This suggests that
airway and parenchymal inflammation is a main source of
oxidants in subjects with developed COPD. Elevated levels
of circulating lipid peroxidation products were also
observed in the blood of patients with COPD and in
asymptomatic cigarette smokers (13,14). Moreover, periph-
eral leukocytes from cigarette smokers release more reactive
oxygen species than cells isolated from blood of healthy
volunteers who had never smoked (15). In addition,
cigarette smoking induces ultra-weak chemiluminescence
of blood in humans (16). These indicate that COPD
subjects express airway and systemic oxidative stress (1).
N-acetylcysteine (NAC) is a widely used mucolytic drug
with anti-oxidant properties (17). Due to its sulphydryl
group it can reduce disulfide bonds and decrease bronchial
mucus viscosity. It serves as a precursor for intracellular
synthesis of glutathione (GSH) and may directly scavenge
reactive oxygen species involved in the pathogenesis of
COPD (17,18). In vitro NAC has been reported to decrease
H2O2-induced damage to epithelial cells (19) and sup-
pressed heat-provoked lipid peroxidation in murine lung
homogenates (20). Intra-peritoneal administration of NAC
significantly reduced endotoxin-induced accumulation of
inflammatory cells in rat lungs (21). NAC given orally
significantly reduced the levels of selected inflammatory
markers in bronchoalveolar lavage fluid of asymptomatic
cigarette smokers (22). Glutathione redox cycle that
consists of GSH, GSH-peroxidase and GSSG-reductase is
the most important system removing H2O2 (23). This mayTABLE 1. Characteristic of study subjects
Whole COPD group
(n=44)
N
Female 23
Male 21
Mean age (yrs) 60+10
FEV, (% pred.) 62+16
FEV1/FVC (%) 57+14
FEV1 reversibility (% pred.) 5+3
Disease duration, (yrs) 10+8
Exacerbations per year 3+2
FEV1 : forced expiratory volume in 1 sec; FVC: forced vital cap
of predicted value.
The predicted values were derived from the European Commu
The duration of disease was calculated from the date a firm di
The NAC-group included six current smokers (present cigarette
consumption 24?6+15?6 pack-years) and 12 ex-smokers (24?
months). In the placebo-group five COPD subjects were curren
and eight were ex-smokers (29?1+24?4 pack-years; time from salso decompose lipid peroxides as it is an inhibitor of the
lipid peroxidation process.
Therefore, in this study we tested whether long-term
administration of NAC (600mg once a day for 12 months)
can reduce H2O2 and TBARs exhalation and decrease
serum levels of lipid peroxidation products in subjects with
COPD. We report herein that treatment with NAC
significantly reduced H2O2 exhalation but had no effect
on exhaled and circulatory levels of lipid peroxidation
products.
Material and methods
PATIENTS
Forty-four patients with stable mild to moderate COPD
(24) were included in the study (Table 1). Eleven patients
were current smokers (present cigarette consumption 14+7
cigarettes a day, cumulative cigarette consumption 23+15
pack-years), 20 were ex-smokers (26+19 pack-years) and
13 had never smoked. They were recruited from the
Medical University Outpatient Department and had not
used inhaled or oral steroids for 3 months before entering
the trial. COPD subjects were aged 40–75 years, had no
history of allergic diseases (e.g. asthma, allergic rhinitis),
peptic ulcer or intestinal malabsorption, and were not
suffering from active infection due to Mycobacterium
tuberculosis, chronic congestive heart failure and did not
use long-term oxygen therapy. Exclusion criteria were a
known allergy to N-acetylcysteine and evidence of alcohol
or substance abuse. The group of control healthy subjects
included 17 volunteers (Table 1) who had never smoked
and had not suffered from any infectious disease for at leastAC group
(n=22)
Placebo group
(n=22)
Healthy controls group
(n=17)
12 11 7
10 11 10
61+10 59+9 55+7
66+12 59+19 99+4
58+12 57+16 80+1
5+4 5+3 2+1
11+8 9+7
3+2 3+2
acity; FEV1 and FEV1 reversibility are expressed as per cent
nity for Steel and Coal statement (43).
agnosis was made.
consumption 16+6 cigarettes per day, cumulative cigarette
7+17?3 pack-years; time from smoking cessation 121+96
t smokers (12+10) cigarettes a day, 18?9+16?2 pack-years)
moking cessation 153+96 months).
450 M. KASIELSKI AND D. NOWAK3 months prior to the study. They were free of any
medication and had no history of respiratory or atopic
disease.
STUDY PROTOCOL
At a screening visit patient demographic data, relevant
medical history (including COPD-, medication- and smok-
ing-history), and general physical condition were recorded.
Subjects were asked to stop any medication except short-
acting b2-agonists (salbutamol or fenoterol on demand),
inhaled anti-cholinergics (ipratropium bromide 40mg t.i.d.)
and theophylline (300mg b.i.d.) and instructed to come to
the laboratory after a 4-week wash-out period for collection
of expired breath condensate and to perform a lung
function test. The breath condensate was collected between
08?00 and 09?00 hours and then the pre- and post-
bronchodilator (15min after 0?2mg of salbutamol; two
puffs from the metered dose inhaler) spirometry, chest
X-ray and laboratory tests were carried out. A 21-day run-
in period demonstrated that the patient was in a stable
physical state and did not use disallowed drugs. Spirometry
was performed with a Flowscreen (Erich Jaeger GmbH Co.,
Wu¨rzburg, Germany) equipped with software compatible
to American Thoracic Society standards (25) between 09?00
and 11?00 hours and subjects refrained from the use of
inhaled drugs and oral theophylline for 6 and 12 h before
lung function measurement and/or expired breath con-
densate collection, respectively.
Patients were then randomized to receive NAC (Fluimu-
cil, Zambon Group SpA, Milan, Italy) 600mg effervescent
tablets or NAC-placebo effervescent tablets once a day for
12 months. Pre- and post-study safety assessments included
blood pressure, pulse rate, physical examination, 12-lead
electrocardiography, serum chemistry, haematology, urina-
lysis and, if required, a pregnancy test. Throughout the
study each patient visited the centre every month to return
unused medications, the completed diary card, and to
receive the new drug supplies and diary. The patient had to
take at least 80% of his medication in order to be
considered compliant. Week-time respiratory symptoms
scores (cough episodes, diculty in breathing, amount and
ease in bringing up sputum) were recorded by the patients
every week on a scale from 0 (no symptoms) to 4
(symptoms prevented normal daily activities) and all details
regarding the medications taken were recorded in the diary
card. The color of sputum and number of days with fever
more than 388C were recorded too. Also, all adverse events
were recorded and their relationships to tested medication
were assessed.
The duration of exacerbation was calculated from the
date of first medical intervention to the last control date or
to the discharge date if patient had been hospitalized.
Exacerbations were treated according to the normal local
clinical practice. A complete physical examination was
carried out at the screening visit, randomization visit and at
the end of study. Since cigarette smoking may change H2O2
exhalation (10) patient’s smoking habit was monitored
every three visits. Ten patients from the NAC group and 11patients from the placebo group were regularly taking
theophylline in the stable dose 300mg b.i.d. during the
study. All patients were treated with short-acting b2-
agonists (on demand) and inhaled anti-cholinergics (ipra-
tropium bromide 40mg t.i.d). Treatment with inhaled
steroids, long acting b2-agonists, mucolytics and anti-
tussive drugs was not allowed throughout the study. The
use of oral or intravenous steriods was allowed only for the
treatment of respiratory exacerbations but for no longer
than 4 weeks. Patients were asked to contact the
investigator if any symptoms worsened and attend the
clinic within 48 h if possible. An acute exacerbation was
defined as a worsening of the previous stable clinical status
with presence of at least one of the following: increased
sputum purulence and/or volume, increased dyspnoea,
wheeze or chest tightness (24).
This study was involved in the BREATHE (Bronchitic
Recurrent Exacerbations: Acetylcysteine Transnational
Health-care European) project, a 9-month, randomized,
parallel-group, double-blind, double-dummy, international,
multi-centre trial (26,27). Collection of expired breath
condensate and blood specimens for determination of
oxidative stress markers and 12-month vs. 9-month treat-
ment with NAC or placebo were the only differences from
the BREATHE study protocol (27). These modifications of
the study protocol have been approved by the sponsor—
Zambon Group (Milan, Italy), and by the Medical
University of Lodz Ethics Committee. All subjects gave
informed consent before participation.
COLLECTION OF EXPIRED BREATH
CONDENSATE
Expired breath condensate was collected between 08?00 and
09?00 hours during the randomization visit and then every 3
months over 1 year during treatment with NAC or placebo
as described previously (10,28).
Subjects were asked to breathe out spontaneously
through a mouthpiece with a saliva trap connected to the
tube and to breathe in with the mouthpiece removed, for
20min. Each subject wore a noseclip and rinsed their
mouth with distilled water just before and at 7 and 14min
of collection in order to reduce the possible H2O2 and
TBARs evaporation from saliva and nasal spaces (10,28,
29). Patient respiratory rate during expired breath con-
densate collection ranged from 17 to 22 breaths
min71. Previous studies showed that a five-fold rise in
respiratory frequency and minute ventilation did not
significantly change the concentration of H2O2 in expired
breath condensate (29). The obtained condensate
(3–5ml) was immediately used for H2O2 and TBARs
determination.
COPD subjects who were current smokers had to refrain
from cigarette smoking for 12 h before the visit. If the
patient failed to refrain from smoking the visit was re-
scheduled within 1–3 days.
Since exacerbation causes the rise in exhaled H2O2 (8) the
breath condensate was collected at least 4 weeks after the
last day of a COPD exacerbation. Our preliminary
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2 weeks after the end of an exacerbation. Therefore, in eight
subjects (three from the NAC group and five from the
placebo group) the breath condensate collection was
delayed by 7–15 days.
MEASUREMENT OF HYDROGEN
PEROXIDE IN EXPIRED BREATH
CONDENSATE
The concentration of H2O2 in expired breath condensate
was measured according to the method of Ruch et al. (30).
Briefly, 600ml of expired breath condensate was mixed with
600 ml of HRP solution (1Uml71) containing 100 mM
homovanillic acid and was incubated for 60min at 378C.
The sample was then mixed with 150ml 0?1M glycine-NaOH
buffer (pH 12?0) with the addition of 25mM EDTA. The
homovanillic acid oxidation product as a measure of the
amount of H2O2 was determined spectrofluorimetrically
using a Perkin Elmer Luminescene Spectrometer LS-50B
(Norwalk, CT, U.S.A.) Excitation was at 312 nm and
emission was measured at 420 nm. As opposed to our
previous studies (10,28) (in which the results were expressed
in nM of H2O2 per sample) readings were converted into mM
using the regression equation Y=(X–X0) 0?06764 (where
Y=mM of H2O2 l
71 of expired breath condensate; X=
intensity of emission at 420 nm expressed in arbitrary units;
X0=intensity of emission given by reference sample
receiving distilled water instead of breath condensate).
The lower limit of H2O2 detection was 0?083mM (9). The
intra-assay variability was 1?3%, 1?8%, and 1?9% for
standard solutions of 0?1 mM, 0?25mM and 0?5 mM H2O2
(n=3), respectively.
MEASUREMENT OF THIOBARBITURIC
ACID-REACTIVE SUBSTANCES IN EXPIRED
BREATH CONDENSATE
The content of TBARs in breath condensate was deter-
mined as previously described (28) except that results are
expressed in mM (9) instead of nM per sample. Briefly, 100 ml
of the condensate was mixed with 2ml of thiobarbituric
acid (TBA) solution (0?67 g TBA dissolved in 100ml of
deionized water, then diluted 1:1 with glacial acetic acid),
boiled for 30min, allowed to cool in ambient temperature
and then chromogen was extracted into 2?5ml of butanol
by vigorous shaking for 1min. Following centrifugation
(10min, 1500 g, 258C), TBARs were measured spectro-
fluorimetrically, excitation at 515 nm, emission at 546 nm
(31). Readings were converted into mM using the regression
equation Y=0?12X70?07 (where Y=mM of TBARs,
X=intensity of emission at 546 nm expressed in arbitrary
units). Tetramethoxypropane (0?01–50 mM) was used as an
external standard and the method sensitivity was 0?05mM
(9). The intra-assay variability was 2?1% and 2?9% for
standard solutions of 0?1mM and 0?5 mM tetramethoxypro-
pane (n=3), respectively.ASSESSMENT OF LIPID PEROXIDATION
PRODUCTS IN SERUM
Aliquots of 10ml of blood were collected from the patients
at the same time points as expired breath condensate
between 09?00 and 10?00 hours. The samples were
centrifuged (1500 g, 10min) and the obtained serum stored
at 7808C until measurements of TBARs and lipid
peroxides were collected, but no longer than 3 weeks.
TBARs in serum
In total, 0?5ml of 0?05M H2SO4 and 0?25ml of 1?23M
trichloroacetic acid were added to 0?05ml of serum, mixed
and then centrifuged for 10min (1500 g, 48C). The super-
natant was discarded and 2ml of distilled water and the
following mixtures were added to the tubes: 0?01ml of
0?1% solution of butylated hydroxytoluene in methanol;
0?5ml of the solution of TBA and acetic acid (0?67 g of
TBA were dissolved in 100ml of distilled water, and mixed
shortly before experiment in 1:1 proportion with glacial
acetic acid). The obtained mixture was incubated for 30min
in a water bath at 1008C in tightly closed tubes. After
cooling, 2?5ml of butanol were added to the tubes and after
intensive shaking, centrifuged for 10min (1500 g, 208C).
Measurements were made in the supernatant of butanol
layer. Fluorescence was measured at an excitation wave-
length of 515 nm and an emission wavelength of 546 nm.
Readings were converted into mM using the calibration
curve obtained for tetramethoxypropane (0?01–50 mM). The
control contained water instead of serum. The results were
expressed in mM of serum.
Lipid peroxides
In total, 0?1ml of 8?1% sodium dodecyl sulfate and 0?75ml
of 20% acetic acid (pH 3?5), as well as 0?75ml of 0?8%
solution of TBA and 0?3ml of distilled water, were added to
0?1ml aliquots of serum. The obtained mixture was then
incubated for 60min in a water bath at 1008C. After
cooling, 2?5ml of butanol and pyridine (ratio of 25:1) were
added to the samples and mixed vigorously. The samples
were centrifuged for 10min (1500 g, 208C). Absorbance was
measured in the upper (organic) phase at a wavelength of
l=532 (Ultrospec 2000, Pharmacia LKB), in relation to
organic phase of the control sample (32). Control contained
water instead of serum. The results were expressed in
absorbance units per 0?1ml of serum (A532).
STATISTICAL ANALYSIS
Demographic and clinical data are expressed by mean+SD.
Results are presented both: as mean+ standard deviation
(SD) and as median and quartile range (qr) (in square
brackets). For readings that gave results below the method
sensitivity the H2O2 and TBARs concentration in expired
breath condensate was assumed as 0mM. Clinical and
demographic data were compared by a t-test for
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placebo groups and time-courses of H2O2 and TBARs
exhalation were analysed using the Mann-Whitney U-test,
Friedman ANOVA and Wilcoxon matched-paired test,
respectively. Correlation coecients were calculated by the
Spearman test.
In all cases a P-value of 50?05 was considered
significant.
Results
The baseline (before randomization) concentrations of
H2O2 and TBARs in expired breath condensate of whole
COPD group (n=44) were 10- and 12-fold higher than in
healthy controls and reached 0?48+0?67mM and
0?48+0?86 mM, respectively [median=0?19mM, qr=0?73
and median=0?00 mM, qr=0?55].
The associations between exhaled H2O2 and TBARs and
cigarette smoking habit, disease duration, and other clinical
parameters in these COPD patients have been described
elsewhere (9). Twenty-two COPD subjects received NAC
and 22 were in the placebo group. The groups did not differ
in terms of age, disease duration, spirometric parameters,
smoking habit, baseline concentration of H2O2 and TBARs
in expired breath condensate and serum levels of lipid
peroxidation products (Tables 1 and 2). Patient’s smoking
habit did not change significantly over the study period.
The mean daily cigarette consumption at the end of the
study was similar in the NAC receivers and in the placebo
group (15+7 vs. 13+9). In addition, no patient stopped or
started cigarette smoking during the 12-month observation.
The number of adverse events was low: two in the NAC
group and three in the placebo group. They consisted of
gastrointestinal discomfort, pyrosis and epigastralgia. No
clinically significant changes in haematology, serum chem-
istry, electrocardiography or urinalysis were reported in
both groups over the study period (data not shown) and all
subjects finished the study according to the protocol. The
number of exacerbation episodes and antibiotic treatment
courses was 11 and six in NAC receivers and 19 and nine in
the placebo group, respectively. The significant reduction of
acute exacerbation episodes related to long-term (9-month)
administration of NAC in the whole group of 295 COPDTABLE 2. Baseline exhalation of H2O2 and TBARs and
concentration of serum lipid peroxidation products in
COPD subjects
Variable NAC-group
(n=22)
Placebo-group
(n=22)
P
Exhaled H2O2 (mM) 0?55+0?68 0?43+0?52 NS
Exhaled TBARs (mM) 0?48+0?46 0?47+0?73 NS
Serum TBARS (mM) 12?7+6?1 15?5+6?7 NS
Serum LP (A532) 0?08+0?18 0?09+0?13 NSsubjects who completed the BREATHE study has been
described elsewhere (26,27).
EFFECTS OF NAC ON H2O2 AND TBARS
EXHALATION
The effect of NAC administration on H2O2 exhalation by
COPD patients is shown in Fig.1. The mean concentrations
of H2O2 in expired breath condensate did not differ between
the placebo and the NAC group up to 6 months of
treatment. After 9 and 12 months of treatment significant
differences were observed. At the end of study (12-month
treatment), the NAC group exhaled 2?7-fold less H2O2 than
the placebo group (0?15+0?23 mM vs. 0?40+0?25 mM,
P50?04) [median=0?00mM, qr=0?32 vs. median=0?36 mM,
qr=0?51]. The H2O2 levels in expired breath condensate of
COPD subjects who received the placebo did not change
significantly over the 12-month treatment period
(0?43+0?52 mM) at the start of study vs. 0?40+0?25mM
after 12 months of treatment) [median=0?45, qr=0?68 vs.
median=0?36, qr=0?51]. In the NAC group H2O2 levels
gradually decreased with time and a significant difference
from baseline value was already noted after 6 months of
treatment (0?21+0?31 mM vs. 0?55+0?68 mM, P50?03)
[median=0?14 mM, qr=0?32 vs. median=0?21 mM,
qr=1?28]. In contrast to H2O2 no differences were found
in TBARs exhalation between the NAC group and placebo
receivers at any time-point (Fig. 2). Also, no significant
differences from baseline TBARs concentrations were
observed for both study treatments over the whole period.
EFFECT OF NAC ON SERUM LEVELS OF
LIPID PEROXIDATION PRODUCTS AND
ASSOCIATIONS BETWEEN MEASURED
VARIABLES
Administration of NAC had no significant effect on serum
concentrations of TBARs and lipid peroxides in COPD
subjects (Table 3). No differences between the placebo and
NAC groups were found with respect to both lipid
peroxidation products at any time-point. No significant
association was found between exhaled TBARs and
concentration of serum lipid peroxides in the NAC and
placebo group at any time-point. In addition, no associa-
tions between exhaled H2O2 and serum lipid peroxidation
products were observed in the NAC group over the whole
study period (data not shown).
Discussion
We found that long-term administration of NAC 600mg
daily decreased H2O2 exhalation in COPD subjects. The
significant decline in H2O2 levels in expired breath
condensate was not observed before 9 months of treatment
when compared to the placebo group. The increase in
activity of the GSH–GSH peroxidase system that effectively
decomposes H2O2 (17) may be a possible explanation for
FIG. 1. The concentration of H2O2 in expired breath condensate of COPD patients receiving NAC 600 mgday
71 (*) or
placebo (&)for 12 months. Significantly different from placebo (*P50?04; **P50?05). Significantly different from baseline
(#P50?03; ##P50?02; ###P50?008).
FIG 2. No significant differences between the NAC (*) and placebo (&) groups were observed over the whole treatment
period.
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administration on the concentrations of GSH in bronch-
oalveolar lavage fluid or epithelial lining fluid gave
controversial results (33–36). NAC in a daily dose up to
1800mg administered for 5 days or 600mg for 2 weeks didnot significantly increase the concentration of GSH or
cysteine in bronchoalveolar lavage fluid of COPD subjects
(33) and healthy volunteers (34), respectively. On the other
hand, the same dose of NAC as tested in COPD subjects
was able to increase the GSH level in bronchoalveolar
TABLE 3 Effect of long-term administration of NAC on serum concentrations of TBARs (mM) and lipid peroxides (A532) in
COPD subjects
Duration of treatment (months)
Variable Treatment Baseline 3 6 9 12
TBARs NAC 13+6 16+7 18+9 17+8 15+6
TBARs Placebo 16+7 19+12 15+8 14+3 14+6
LP NAC 0?08+0?18 0?07+0?09 0?06+0?06 0?13+0?25 0?08+0?07
LP Placebo 0?09+0?13 0?05+0?04 0?06+0?03 0?07+0?04 0?07+0?05
No significant differences were found between measured variables in the NAC and placebo group.
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(35). In another study NAC given orally raised the
pulmonary GSH concentration in subjects undergoing
routine diagnostic bronchoscopy due to suspicion of a lung
tumour (36). However, although, oral administration of
NAC for several days did not elevate the concentration of
GSH in the airways of COPD subjects the occurrence of
this mechanism cannot be excluded in the case of a long-
term treatment with NAC.
Inflammatory cells including polymorphonuclear leuko-
cytes are important source of exhaled H2O2 in COPD
subjects. Cigarette smokers treated with NAC 200mg t.i.d.
for 8 weeks revealed a decrease in the concentration of
humoral markers of inflammatory cells including lactofer-
rin, eosinophil cationic protein and chemotactic activity for
neutrophils in bronchoalveolar lavage fluid compared to
baseline values (22). Since our COPD patients were treated
for 12 months and more than half of them were current
cigarette smokers or ex-smokers the NAC-induced suppres-
sion of inflammatory cell activity in the airways may be an
additional mechanism responsible for decrease in H2O2
exhalation. Exacerbation of COPD causes the rise in H2O2
exhalation (8). In our study the number of exacerbation
episodes in subjects treated with NAC was lower than in the
placebo group. However, collection of breath condensate at
least 28 days after the end of exacerbation ensures that
decrease in the number of exacerbation episodes seems to
be not responsible for NAC-induced suppression of H2O2
exhalation in COPD patients.
Exhaled H2O2 is recognized as a biomarker of oxidative
stress that plays important role in the development and
progression of COPD (1). The myeloperoxidase (MPO)–
H2O2–chloride system generates hypochlorous acid that is
the most potent inactivator of a1-proteinase inhibitor. This
leads to a rise in elastase activity in the lower airways and to
the development of pulmonary emphysema. H2O2 in the
presence of iron can also generate hydroxyl radicals,
inducing peroxidative damage to almost all biomolecules.
In addition, oxidative stress via activation of nuclear factor
NF-kB enhances synthesis and release of proinflammatory
cytokines 1L-8 and TNFa. Anti-oxidants that decompose
H2O2 (including NAC) are able to prevent NF-kB
activation in cell cultures (37). Thus, suppression ofpulmonary H2O2 formation in response to treatment with
NAC may break various processes that contribute to
progression COPD (1). Moreover, the MPO–H2O2 system
can promote oxidation of nitrite to intermediates that are
capable of nitrating various proteins (38). Recent studies
have shown that nitration of tyrosine residues in surfactant
protein A (SP-A) decreases its ability to bind to mannose
receptors on the surface of immune effector cells. (39).
Given the proposed role of SP-A in the host defense, its
nitration may facilitate the invasion of micro-organisms
into airways (38). The NAC-induced suppression of H2O2
generation may inhibit deleterious modification of SP-A
and may be one of the mechanisms responsible for
prevention of acute exacerbations of COPD evoked by
long-term administration of this drug (40).
Exhaled TBARs did not decrease in response to
treatment with NAC. This is surprising in the light of the
ability of H2O2 to induce peroxidation of variety of
biomolecules, including lipids, with subsequent generation
of TBARs (41). In our previous studies we did not observe
any associations between exhaled H2O2 and TBARs in the
group of stable COPD subjects who participated in the trial
reported herein (9). The lack of association between these
two variables over a 12-month observation period suggests
that exhaled H2O2 may represent a pool of reactive oxygen
species not involved in lipid peroxidation processes. On the
other hand, exhaled TBARs may originate from enzymatic
lipid peroxidation (usually enhanced in the site of
inflammation) (41) and therefore did not associate with
exhaled H2O2 and were not affected by long-term treatment
with NAC. Similarly, administration of NAC did not
significantly change the serum levels of TBARs and lipid
peroxides. This is consistent with results of Kleinveld et al.
who found that NAC given orally for 6 weeks in healthy
volunteers did not reduce the susceptibility of low-density
lipoprotein to in-vitro oxidation (42). Administration of
NAC may not suciently increase the serum and/or
extracellular fluid anti-oxidant capacity to prevent lipid
peroxidation. On the other hand, NAC and cysteine hardly
penetrate into the hydrophobic micro-environment of lipids
and therefore are not able to protect them from perox-
idative damage. This agrees with the observation that intra-
peritoneal administration of NAC does not inhibit
LONG-TERM USE OF N-ACETYLCYSTEINE IN COPD 455H2O2-induced formation of conjugated dienes (a first lipid
peroxidation product) in murine lungs (20).
In conclusion, we found that long-term administration of
NAC decreases H2O2 exhalation in COPD subjects. This
proves an antioxidant action of drug. However, this
treatment had no influence on concentrations of exhaled
and circulatory end-products of lipid peroxidation. There-
fore, we are not clear about how this reflects NAC-induced
suppression of oxidant-dependent destructive processes in
the airways. The explanation of the exact mechanism
responsible for the decrease in H2O2 exhalation in response
to treatment with NAC and its effect on progression of
COPD requires further studies.
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